FDA Approves Teva's Weltruza, a Once-Monthly Olanzapine Injection for Schizophrenia

Teva Pharmaceutical Industries said on Friday that the U.S. Food and Drug Administration has approved Weltruza, a once-monthly injectable formulation of the antipsychotic olanzapine for adults with schizophrenia, according to CNBC and Seeking Alpha.

What the FDA Approved

Seeking Alpha reported that the medicine is administered once a month and will be available in three doses, describing the product as an "ultra-long-acting injectable antipsychotic containing olanzapine" for the treatment of schizophrenia. Neither report detailed specific boxed-warning language, individual dose strengths, or comparative label provisions relative to other olanzapine-based depot injections, so those specifics are not addressed here.

The drug relies on long-acting injectable technology from French biotech Medincell, which CNBC said is designed to release medicines over extended periods. CNBC also reported that, per Reuters, the long-acting formulation may help address treatment-adherence challenges in schizophrenia and other chronic psychiatric illnesses.

Launch Timing and the Medincell Partnership

Teva, which CNBC said leads development and commercialization of Weltruza, expects to launch the product in the United States "in the coming weeks," according to the company's statement cited by CNBC. No list price has been disclosed in the reporting reviewed, and no peak-sales guidance from Teva or sell-side analysts appears in the available coverage.

Weltruza marks the second U.S.-approved product to emerge from Teva's partnership with Medincell, following Uzedy, a long-acting injectable form of the antipsychotic risperidone that the FDA approved in 2023, CNBC reported. Under the companies' agreement, Medincell may be eligible for up to $112 million in additional development and commercial milestone payments tied to Weltruza, plus royalties on sales, according to CNBC's report.

Market Reaction

CNBC reported that Teva shares were up 2% in Tel Aviv trading at 11:24 GMT on Friday following the announcement. Medincell shares were suspended at the company's own request ahead of the announcement, per the same report. No separate U.S. share price action for Teva was included in the reporting reviewed.

Interpretation: Taken together, the reported details point to a modest, incremental approval rather than a transformative one for Teva's market value on the day of the news; a 2% move on a single exchange, absent accompanying U.S. share data or analyst price commentary in the sourced reports, does not by itself indicate how investors are weighing Weltruza's long-term commercial contribution. Readers should treat the adherence-benefit rationale cited by Reuters as a clinical rationale for the product's design, not as a guaranteed outcome of its FDA approval.

Bottom Line

The FDA has cleared Weltruza, Teva's once-monthly, three-dose olanzapine injection for adult schizophrenia patients, with U.S. launch expected within weeks per Teva's own statement. The approval builds on Teva's existing long-acting injectable partnership with Medincell that previously produced Uzedy, and includes potential milestone payments of up to $112 million for Medincell plus royalties. Specifics on pricing, peak-sales forecasts, detailed label language, and head-to-head clinical differentiation against other long-acting antipsychotic injectables were not available in the reporting reviewed and should be confirmed through Teva's formal prescribing information and subsequent company disclosures as the launch proceeds.